Web Desc
Antibodies as Drugs: Translating Molecules into Treatments
Organizer(s): Paul W. H. I. Parren and Erica Ollmann Saphire
Date: February 25 - March 01, 2018
Location: Whistler Conference Centre, Whistler, BC, Canada
Sponsored by Bioverativ Therapeutics, Genentech, Inc., ImmunoGen, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Regeneron Pharmaceuticals, Inc.
Summary of Meeting:
Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.
Scholarship Deadline: October 24 2017
Discounted Abstract Deadline: October 24 2017
Abstract Deadline: November 21 2017
Discounted Registration Deadline: December 19 2017
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Bioverativ TherapeuticsGenentech, Inc.ImmunoGen, Inc.Merck & Co., Inc.OncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.
We gratefully acknowledge additional support for this conference from:
Adipogen International
Berkeley Lights, Inc.
The Antibody Society
Zymeworks
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

EMBO Young Investigator Programme

Genmab A/S

ImmunoGen, Inc.

Xencor, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI136247-01
Funding for this conference was made possible (in part) by 1 R13 AI136247-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, February 25 | 4:00PM - 8:00PM
Arrival and Registration
Room: Grand Foyer


Sunday, February 25 | 6:00PM - 8:00PM
Welcome Mixer
Room: Grand Foyer
No registration fees are used to fund alcohol served at this function.

Monday, February 26 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky C


Monday, February 26 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B

Speaker 1 of 4
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

Monday, February 26 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B

Speaker 2 of 4
* Erica Ollmann Saphire, La Jolla Institute for Immunology, USA

Monday, February 26 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B

Speaker 3 of 4
* David I. Watkins, University of Miami, USA

Monday, February 26 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B

Speaker 4 of 4
Dennis R. Burton, The Scripps Research Institute, USA
Molecular Vaccine Design Guided by Human Anti-Viral Antibodies

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 1 of 7
* David I. Watkins, University of Miami, USA

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 2 of 7
George Georgiou, University of Texas at Austin, USA
The Human Serological and BCR Antibody Repertoires in Cancer, Autoimmunity or following Vaccination

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B


Coffee Break

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 4 of 7
Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Systematic Analysis of Monoclonal Antibodies Against Ebola Virus GP Defines Features that Contribute to Protection

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 5 of 7
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Lessons from the Analysis of the Immune Response to P. falciparum

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 6 of 7
Arthur S. Kim, Washington University School of Medicine, USA
Short Talk: Identification of Protective Antibody Epitopes on the Eastern Equine Encephalitis Virus Envelope Protein

Monday, February 26 | 9:00AM - 11:30AM
Protective Antibody Responses
Room: Sea to Sky B

Speaker 7 of 7
Sarah Elliott, Wistar Institute, USA
Short Talk: DNA-Encoded Monoclonal Antibody (DMAb) for Acute Prophylaxis Against Influenza

Monday, February 26 | 11:30AM - 1:00PM
Poster Setup


Monday, February 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Grand Foyer


Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 1 of 9
* Ann J. Hessell, Oregon Health & Science University, USA

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 2 of 9
Tongqing Zhou, NIAID, National Institutes of Health, USA
Structural Basis of Zika-Neutralizing Monoclonal Antibodies Elicited in Immunized Macaque Monkeys

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 3 of 9
Brett W. Jagger, Washington University, USA
Efficacy of Zika Virus Vaccines Against Zika Infection in Mice During Pregnancy

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 4 of 9
Laura A. Powell, Vanderbilt University, USA
Cross-Reactive and Potently Neutralizing Antibody Response in a Donor Naturally Infected with Ross River Virus

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 5 of 9
Natasha D. Durham, Tufts University, USA
Neutralizing Antibodies Remodel the Conformational Landscape of Ebola GP

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 6 of 9
Hideki Hasegawa, National Institute of Infectious Diseases, Japan
Enhancement of Anti-Viral Effects of an Intranasal Inactivated Influenza Vaccine-Derived Broadly Neutralizing Antibody by IgA Polymerization

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 7 of 9
Bryan Briney, The Scripps Research Institute, USA
Exceptionally Deep Antibody Repertoire Sequencing to Guide mAb Discovery and Development

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 8 of 9
Ron Diskin, Weizmann Institute of Science, Israel
Targeting TfR1-Tropic Arenaviruses at their Achilles Heel: Structure-Based Rational Design of Universal Immunotherapy

Monday, February 26 | 2:30PM - 4:30PM
Workshop 1: Antibodies and Protection
Room: Sea to Sky B

Speaker 9 of 9
Matthijs M. Jore, Radboud University Medical Center, Netherlands
Engineered Antibodies Against Plasmodium Transmission from Man to Mosquito

Monday, February 26 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Monday, February 26 | 5:00PM - 7:00PM
From Molecules to Vaccines
Room: Sea to Sky B

Speaker 1 of 5
* Erica Ollmann Saphire, La Jolla Institute for Immunology, USA

Monday, February 26 | 5:00PM - 7:00PM
From Molecules to Vaccines
Room: Sea to Sky B

Speaker 2 of 5
Nancy L. Haigwood, Oregon Health & Science University, USA
Antibody-Based HIV Therapeutics: 'Hit Early, Hit Hard'

Monday, February 26 | 5:00PM - 7:00PM
From Molecules to Vaccines
Room: Sea to Sky B

Speaker 3 of 5
James E. Crowe, Jr., Vanderbilt University Medical Center, USA
Genetic and Structural Basis for Virus Neutralization by Human Antibodies

Monday, February 26 | 5:00PM - 7:00PM
From Molecules to Vaccines
Room: Sea to Sky B

Speaker 4 of 5
Robert F. Garry, Tulane University Health Sciences Center, USA
Antibody Treatment of Lassa Virus: From the Field to the Lab and Back

Monday, February 26 | 5:00PM - 7:00PM
From Molecules to Vaccines
Room: Sea to Sky B

Speaker 5 of 5
Ruoke Wang, Tsinghua University, China
Short Talk: Delineating Antibody Recognition Against Envelope Protein of Zika Virus during Natural Infection

Monday, February 26 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky C
No registration fees are used to fund alcohol served at this function.

Monday, February 26 | 7:30PM - 10:00PM
Poster Session 1
Room: Grand Foyer


Tuesday, February 27 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky C


Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 1 of 8
Janine Schuurman, Genmab B.V., Netherlands
Therapeutic Antibody Panorama: Highways, Scenic Routes and Dead-Ends



Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 2 of 8
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Principles of Effective Antibody Therapeutics

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B


Coffee Break

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 4 of 8
Marie H. Kosco-Vilbois, AC Immune, Switzerland
Creating Molecules that Succeed in the Clinic

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 5 of 8
Emma M. Lees, Bristol Myers Squibb, USA
JTX-2011: Mechanism of Action of an Agonist Antibody Targeting ICOS

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 6 of 8
* Ira Mellman, Genentech, Inc., USA
Antibodies in Cancer Immunotherapy

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 7 of 8
Cory Brooks, California State University, Fresno, USA
Short Talk: Glycosylation of MUC1 Influences the Binding of a Therapeutic Antibody by Altering the Conformational Equilibrium of the Antigen

Tuesday, February 27 | 8:00AM - 11:45AM
Antibodies as Biopharmaceuticals
Room: Sea to Sky B

Speaker 8 of 8
Alexander W. Koch, Novartis Institutes for BioMedical Research, USA
Short Talk: Targeting Coagulation Factor XI (FXI) for Thrombosis Prevention

Tuesday, February 27 | 11:45AM - 5:00PM
On Own for Lunch


Tuesday, February 27 | 11:45AM - 1:00PM
Poster Setup
Room: Grand Foyer


Tuesday, February 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Grand Foyer


Tuesday, February 27 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 1 of 6
* Pierre Bruhns, Institut Pasteur, France

Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 2 of 6
Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 3 of 6
Jan Terje Andersen, Oslo University Hospital, Norway
HERA: A Human Endothelial Cell-Based Recycling Assay for Screening of FcRn Targeted Molecules

Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 4 of 6
Jeffrey S. Miller, University of Minnesota, USA
Strategies to Use Trispecific Killer Engagers to Make NK Cells Antigen Specific


Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 5 of 6
Julie M. Fox, Washington University, USA
Short Talk: Antibody Therapy Reduces Chikungunya Virus Disease through an FcgR-Dependent Mechanism

Tuesday, February 27 | 5:00PM - 7:15PM
Antibody Fc-Mediated Mechanisms I
Room: Sea to Sky B

Speaker 6 of 6
James A. Ernst, Genentech, Inc., USA
Short Talk: Optimizing Antibodies for Targeting the Tau Protein for Alzheimer's Disease and Other Tauopathies

Tuesday, February 27 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Sea to Sky C
No registration fees are used to fund alcohol served at this function.

Tuesday, February 27 | 7:30PM - 10:00PM
Poster Session 2
Room: Grand Foyer


Wednesday, February 28 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky C


Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 1 of 8
* Marjolein van Egmond, VU University Medical Center, Netherlands

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 2 of 8
Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Complement Activation at the Molecular Level

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 3 of 8
Suzan Huberdina Maria Rooijakkers, University Medical Center Utrecht, Netherlands
EMBO Young Investigator Lecture: Antibody-Mediated Killing of Bacteria by Complement

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B


Coffee Break

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 5 of 8
Galit Alter, MIT and Harvard University, USA
Correlate Guided Approaches to Develop Antibodies Against Ebola Virus Infection

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 6 of 8
Pierre Bruhns, Institut Pasteur, France
Analyses of Single Ab-Secreting Cells using Droplet Microfluidics

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 7 of 8
David P. Humphreys, UCB Pharma, UK
Short Talk: On Target Hexamerisation of IgG1 Driven by a Mutant form of IgM Tail-Piece C-Terminal Fusion

Wednesday, February 28 | 8:00AM - 11:15AM
Antibody Fc-Mediated Mechanisms II
Room: Sea to Sky B

Speaker 8 of 8
Dieke J. van Rees, Sanquin Research and Landsteiner Laboratory, Netherlands
Short Talk: Sodium Stibogluconate in Conjunction with CD47-SIRP Checkpoint Blockade Enables Rituximab-Mediated Killing of B Lymphoma Cells by Neutrophils

Wednesday, February 28 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 1 of 9
* Ida Hiemstra, Genmab, Netherlands

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 2 of 9
* Devin Sok, International AIDS Vaccine Initiative, USA
Non-Human Primate Pharmacokinetics of HIV Broadly Neutralizing Antibodies Isolated from Cow Immunizations

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 3 of 9
Amarendra Pegu, NIAID, National Institutes of Health, USA
Trispecific Antibodies Mediate Highly Potent and Broad Neutralization of HIV and Confer Expanded Protection Against SHIV Infection in Macaques

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 4 of 9
Sanjay Ram, University of Massachusetts, USA
Potentiation of Efficacy of a Candidate Immunotherapeutic Anti-Neisseria Gonorrhoeae Antibody by Enhancing IgG Fc Hexamer Formation

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 5 of 9
Nina G. Caculitan, Genentech, Inc., USA
Discovery of the Determinants of Antibody-Drug Conjugate Efficacy and a Novel Resistance Mechanism to Anti-HER2 Therapeutics

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 6 of 9
Jordana Griffiths, University of Southampton, UK
Targeting OX40 in Cancer Immunotherapy

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 7 of 9
John Engelhardt, Bristol-Myers Squibb Company, USA
Next Generation Anti-CTLA-4 Antibodies

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 8 of 9
Ezio Bonvini, MacroGenics, Inc, USA
Tailoring Cytolytic Activity, Proliferation and Cytokine Release via CD3 Engineering of DART® Molecules for Redirected T-cell Killing

Wednesday, February 28 | 2:30PM - 4:30PM
Workshop 2: Therapeutic Antibodies
Room: Sea to Sky B
- Structural aspects of antibodies, novel insights
- Novel therapeutic antibody formats
- Novel antibody technologies
- From target to therapy
- Newly approved and upcoming antibody therapeutics
Speaker 9 of 9
Michael Johnston, Queen's University Belfast, UK
Development of AMG 655 Conjugated Polymeric Nanoparticles Targeting Death Receptor 5 for the Treatment of Pancreatic Cancer

Wednesday, February 28 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Wednesday, February 28 | 5:00PM - 7:00PM
Exploiting Effector Cell Responses
Room: Sea to Sky B

Speaker 1 of 5
* Pamela J. Bjorkman, California Institute of Technology, USA

Wednesday, February 28 | 5:00PM - 7:00PM
Exploiting Effector Cell Responses
Room: Sea to Sky B

Speaker 2 of 5
Sergio A. Quezada, University College London, UK
Regulatory T Cells, Polymorphisms and Response to Checkpoint Blockade: From Mechanisms to Potential Biomarkers

Wednesday, February 28 | 5:00PM - 7:00PM
Exploiting Effector Cell Responses
Room: Sea to Sky B

Speaker 3 of 5
Bertrand Routy, Centre hospitalier de l’Université de Montréal, Canada
The Gut Microbiota as a Novel Predictor of Immune Checkpoint Inhibitors Response?

Wednesday, February 28 | 5:00PM - 7:00PM
Exploiting Effector Cell Responses
Room: Sea to Sky B

Speaker 4 of 5
Marjolein van Egmond, VU University Medical Center, Netherlands
Translating Antibody–Effector Cell Cross-Talk to Immunotherapy

Wednesday, February 28 | 5:00PM - 7:00PM
Exploiting Effector Cell Responses
Room: Sea to Sky B

Speaker 5 of 5
Maria Mar Naranjo, Centre National de la Recherche Scientifique, France
Short Talk: Key Immunomodulatory Role of Neutrophils in the Induction of Protective Immunity by Antiviral Monoclonal Antibodies

Wednesday, February 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky C
No registration fees are used to fund alcohol served at this function.

Thursday, March 01 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky C


Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 1 of 8
* Janine Schuurman, Genmab B.V., Netherlands

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 2 of 8
Ugur Sahin, BioNTech AG, Germany
Antibody and mRNA-Based Therapeutics

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 3 of 8
Mark Cobbold, AstraZeneca, USA
Retargeting T Cells for Tumor Therapy

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B


Coffee Break

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 5 of 8
Markus Schmid, University of Zurich, Switzerland
Paracrine Delivery of Therapeutic Proteins

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 6 of 8
Johannes Lutz, Curevac AG, Germany
mRNA-Encoded Antibodies for Passive Immunization

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 7 of 8
Kalie Mix, Sanofi, USA
Short Talk: Cytosolic Delivery of Antibodies

Thursday, March 01 | 8:00AM - 11:15AM
Novel Ways to Deliver Antibody Therapy
Room: Sea to Sky B

Speaker 8 of 8
Jeffrey J. Bunker, University of Chicago, USA
Short Talk: Natural Polyreactive IgA Antibodies Coat the Intestinal Microbiota

Thursday, March 01 | 11:15AM - 5:00PM
On Own for Lunch


Thursday, March 01 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Thursday, March 01 | 5:00PM - 6:45PM
From Molecules to the Clinic
Room: Sea to Sky B

Speaker 1 of 3
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

Thursday, March 01 | 5:00PM - 6:45PM
From Molecules to the Clinic
Room: Sea to Sky B

Speaker 2 of 3
David E. Szymkowski, Szymkowski David, USA
Exploring Novel Mechanisms of Action and Clinical Outcomes of Therapeutic Antibodies Fc-Engineered to Optimally Engage Fc Gamma RIIb

Thursday, March 01 | 5:00PM - 6:45PM
From Molecules to the Clinic
Room: Sea to Sky B

Speaker 3 of 3
John M. Lambert, USA
Antibody-Drug Conjugates (ADCs): The Magic Bullet Revisited

Thursday, March 01 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Sea to Sky B


Thursday, March 01 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky C
No registration fees are used to fund alcohol served at this function.

Thursday, March 01 | 8:00PM - 11:00PM
Entertainment
Room: Sea to Sky C
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 01 | 8:00PM - 11:00PM
Cash Bar
Room: Sea to Sky C


Friday, March 02 | 10:24AM - 10:24AM
Departure


*Session Chair.